Microparticles as a strategy for low-molecular-weight heparin delivery

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1783-1792

  Oliveira, Samantha S M ^a   Oliveira, Fabiana S ^a   Gaitani, Cristiane M ^a   Marchetti, Juliana M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biodegradable polymers; Controlled release; dissolution; Double emulsification solvent evaporation; Enoxaparin sodium; macromolecular drug delivery; Microencapsulation; PLGA

Indexed keywords

ENOXAPARIN; NANOPARTICLE; POLYGLACTIN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EMULSION; ENCAPSULATION; HYDROPHILICITY; IN VITRO STUDY; MICROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; TURBIDIMETRY;

EID: 79952226930     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22412     Document Type: Article

References (41)

1. Hirsh J. 1991. Heparin. N Engl J Med 324: 1565-1574.
2. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. 1998. Assessment of outpatient treatment of deep vein thrombosis with low molecular weight heparin. Arch Intern Med 158:2001-2003.
3. Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. 1998. Antithrombotic therapy for venous thromboembolic disease. Chest 114:561S-578S.
4. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, Kovacs J. 1998. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low molecular weight heparin. Arch Intern Med 158:1809-1812.
5. Segal JB, Streiff MB, Hofmann LV, Thornton K, Bass EB. 2007. Management of venous thromboembolism: A Systematic Review for a Practice Guideline Ann Intern Med. 146: 211-222.
6. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. 2008. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:454S-545S.
7. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte L, Maincent P. 2002. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105:230-235.
8. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen, JE. 1998. Heparin and low molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114:489S-510S.
9. Hirsh J, Anand SS, Halperin JL, Fuster V. 2001. Guide to anticoagulant therapy Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 103:2994-3018.
10. Hull RD, Pineo GF, Raskob GE. 1998. The economic impact of treating deep vein thrombosis with low molecular weight heparin: Outcome of therapy and health economy aspects. Haemostasis 28:8-16.
11. Ubrich N, Maincent P. 2006. Recent advances in heparin delivery. Drugs Pharma Sci 158:481-520.
12. Hirsh J. 2001. New anticoagulants. Am Heart J 142:53-58.
13. Hirsh J, Bates SM. 2000. The emerging role of low-molecular-weight heparin in cardiovascular medicine. Prog Cardiovasc Dis 42:235-246.
14. Hirsh J, Raschke R. 2004. Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S-203S.
15. Du Breuil AL, Umland EM. 2007. Outpatient management of anticoagulation therapy. Am Fam Phys 75:1031-1042.
16. Scala-Bertola J, Rabiskova M, Lecompte T, Bonneaux F, Maincent P. 2009. Granules in the improvement of oral heparin bioavailability. Int J Pharm 374:12-16.
17. Ye M, Kim S, Park K. 2010. Issues in long-term protein delivery using biodegradable microparticles. J Control Rel 146: 241-260.
18. Tronto J, Reis MJ, Silverio F, Balbo VR, Marchetti JM, Valim JBJ. 2004. In vitro release of citrate anions intercalated in magnesium aluminium layered double hydroxides. J Phys Chem Solids 65:475-480.
19. Ricci-Júnior E, Marchetti JM. 2006. Preparation, characterization, photocytotoxicity assay of PLGA nanoparticles containing zinc (II) phthalocyanine for photodynamic therapy use. J Microencapsul 23:523-538.
20. Ricci-Júnior E, Marchetti JM. 2006. Zinc (II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. Int J Pharm 310:187-195.
21. Crowder TM, Hickey AJ, Louey MD, Orr N. 2003. A guide to pharmaceutical particulate science. Boca Raton, Florida: Interpharm/CRC.
22. Freitas MN, Marchetti JM. 2005. Nimesulide PLA microspheres as a potential sustained release system for the treatment of inflammatory diseases. Int J Pharm 295:201-211.
23. Venier-Julienne MC, Benoit JP. 1996. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharm Acta Helv 71:121-128.
24. Herrmann J, Bodmeier R. 1998. Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods. Eur J Pharm Biopharm 45:75-82.
25. Jain R, Shah NH, Malick AW, Rhodes CT. 1998. Controlled drug delivery by biodegradable poly(ester) devices: Different preparative by approaches. Drug Dev Ind Pharm 24:703-727.
26. Kissel T, Maretschek S, Packhäuser C, Schnieders J, Seidel N. 2006. Microencapsulation techniques for parenteral depot systems and their application in the pharmaceutical industry. In Microencapsulation: methods and industrial applications; Benita S, Ed. 2nd ed. Boca Raton, Florida: CRC Press, pp 98-122.
27. Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, Hoffman M, Maincent P. 2003. Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Del 10:1-7.
28. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. 2006. Oral bioavailability of a low molecular weight heparin a polymeric delivery system. J Control Rel 113:38-42.
29. Lamprecht A, Ubrich N, Maincent P. 2007. Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm 67:632-638.
30. Ardry M. 1971. Dosage de I'héparine. Bull Ordre Pharm 135:699-708.
31. Charlot G. 1964. Colorimetric determination of elements: Principles and methods. Amsterdam, the Netherlands: Elsevier.
32. Willard HH, Merritt Jr LL, Dean JA, Settle Jr FA. 1988. Instrumental methods of analysis. 7th ed. Belmont: Wadsworth.
33. Morais IPA, Tóth IV, Rangel AOSS. 2006. Turbidimetric and nephelometric flow analysis: Concepts and applications. Spectrosc Lett 39:547-579.
34. Soppimath SH, Aminabhavi MT, Kulkarni, RA, Rudzinski EW. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 70:1-20.
35. Narasimhan B, Peppas NA. 1997. Molecular analysis of drug delivery systems controlled by dissolution of polymer carrier. J Pharm Sci 86:297-304.
36. Luong-Van E, Grøndahl L, Nurcomb V, Cool S. 2007. In vitro biocompatibility of microencapsulated heparan sulfate. Biomaterials 28:2127-2136.
37. Manadas R, Pina ME, Veiga F. 2002. A dissolução in vitro na previsão da absorção oral de fármacos em formas farmacêuticas de liberação modificada. Rev Bras Cienc Farm 38:375-399.
38. Higuchi T. 1961. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 50:874-875.
39. Higuchi T. 1963. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52:1145-1149.
40. Higuchi T, Dayal S, Pitman IH. 1972. Effects of solute-solvent complexation reactions on dissolution kinetics: Testing of a model by using a concentration jump technique. J Pharm Sci 61:695-700.
41. Xie S, Wang S, Zhao B, Han C, Wang M, Zhou W. 2008. Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Coll Surf B Biointerfaces 67:199-204.